Aeolus Pharmaceuticals, Inc.  

(Public, OTCMKTS:AOLS)   Watch this stock  
Find more results for OTC:AOLS
0.225
-0.005 (-2.17%)
Delayed:   1:27PM EST
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.22 - 0.24
52 week 0.19 - 0.55
Open 0.24
Vol / Avg. 24,558.00/21,167.00
Mkt cap 30.57M
P/E     -
Div/yield     -
EPS 0.00
Shares 135.85M
Beta 0.52
Inst. own 79%
Jan 12, 2015
Aeolus Pharmaceuticals Inc at OneMedForum SF
Dec 4, 2014
Aeolus Pharmaceuticals Inc at LD Micro Conference
  

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -21.72% -0.83%
Operating margin -21.72% -0.83%
EBITD margin - -0.83%
Return on average assets -49.74% -2.88%
Return on average equity -129.91% -7.02%
Employees 4 -
CDP Score - -

Address

26361 Crown Valley Pkwy Ste 150
MISSION VIEJO, CA 92691-7324
United States - Map
+1-949-4819825 (Phone)
+1-919-5588686 (Fax)

Website links

Description

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead compound, AEOL 10150, is entering human clinical trials in oncology where it is used in combination with radiation therapy. AEOL 10150 had been tested in two Phase-I clinical trials. AEOL 10150 is a metalloporphyrin designed to neutralize reactive oxygen and nitrogen species. The compound is also being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (pulmonary acute radiation syndrome or Lung-ARS), as well as the gastrointestinal sub-syndrome of acute radiation syndrome (GI-ARS). It is also being developed for use as a countermeasure for exposure to chemical vesicants, such as chlorine gas and sulfur mustard gas. Additionally, Aeolus is developing AEOL 10150 for oncology indications, where it is used in combination with radiation and chemotherapy.

Officers and directors

David C. Cavalier Chairman of the Board, Interim Chief Financial Officer
Age: 45
John L. McManus President, Chief Executive Officer
Age: 48
John M. Clerici Director
Mitchell D. Kaye J.D. Director
Age: 46
Jeffrey A. Scott M.D. Director
Age: 55
John M. Farah Jr., Ph.D. Independent Director
Amit Kumar Ph.D. Independent Director
Age: 35